Epigenetics Market, 2012 to 2023
Epigenetics Market: Epigenetics is a study of heritable changes in gene expression which involves the change in phenotype without changing genotype, which in turn affects the reading of genes by cells. Epigenetic changes are natural and regular processes but also influenced by various factors like lifestyle, environment, age and state of disease. Epigenetic modifications can manifest a common manner of cells which differentiate terminally to end up as liver cells, skin cells, brain cells etc. Epigenetic change may have more damaging effects which can lead to diseases like cancer. Systems like histone modification, non-coding RNA-associated gene silencing and DNA methylation are considered for initiation of epigenetic change sustainably.
Market Outline: Global Epigenetics Market
The surge in the prevalence of cancer, improving funds and aids for the R&D activities, rise in the partnerships between pharmaceutical and biotechnology companies and research institutes, increase in epigenetics application in non-oncology diseases will propel the epigenetics. Moreover, improved advancements in epigenetics technology, untapped potential of emerging markets like India and China are expected to offer many opportunities for the growth of epigenetics market. However, high instrument cost and the dearth of skilled personnel are expected to hamper the growth of the epigenetics market.
The Epigenetics Market is classified on the basis of enzymes, kits and assays, instruments, application, end user, and geography.
Based on enzymes, the Epigenetics Market is segmented into the following
DNA polymerase
Acetylases
DNA ligases
Methyltransferase
RNA ligases
Reverse Transcriptase
Others
Based on instruments, the epigenetics Market is segmented into the following
Next generation sequencers
Mass spectrometers
Sonicators
qPCRs
Others
Based on application, the epigenetics market is segmented into the following
Oncology
Cardiovascular diseases
Metabolic diseases
Inflammatory diseases
Infectious diseases
Based on kits and assays, the epigenetics Market is segmented into the following
Deep sequencing kit
Bisulfate conversion kit
Methyltransferase assays
Chip- seq kits
Immunoprecipitation kits
Histone assay
Based on end-user, the epigenetics Market is segmented into the following
Pharmaceutical and biotechnological companies
Contract research companies
Academic and Research Institutes
Epigenetics has triggered R&D for new drugs for various cancers, chronic and autoimmune disorders. For example, U.S.FDA approved ramucirumab/Cyramza by Eli Lilly for use in combination with folfiri to treat metastatic colorectal cancer and Novartis’s Farydak and Celgene’s Istodax received FDA approval in 2015. Introduction of advanced technologies and potential investments on R&D activities are expected to fuel the growth of epigenetics. Currently, companies are focussing on detection of DNA methylation patterns and histone modification. For example, Epigenomic’s EPI ProColon 1.0, Quest Diagnostic’s ColoVantage, Abbott’s Real Time mS9 are few tests which detect SepT9 DNA methylation biomarker for colorectal carcinoma. Development of high specific antibodies for accurate and rapid detection of modifications of histone core proteins. For example, Abcam developed a multiplex assay kit for the detection of various core histone protein modifications.
Geographically Epigenetics Market is segmented as Latin America, Europe, Asia- Pacific, North America, The Middle East & Africa. North America is expected to account for the largest market share in the regional market of epigenetics due to rise in prevalence of cancer, high funding on R&D, increasing acquisitions and collaborations among large pharma companies, high adaptation and awareness of new technologies and healthcare infrastructure. Asia Pacific is a lucrative market owing to the presence of favourable regulatory framework, high incidence and prevalence of diabetes, cancer and cardiovascular diseases among the population of Asia Pacific countries. Mexico, Brazil, and South Africa are expected to show significant growth due to rising economy, a high prevalence of diseases and presence of high unmet needs.
Some of the players in epigenetics market Illumina, Inc. (U.S.), Abcam plc. (U.K), QIAGEN N.V. (Netherland), New England Biolabs, Inc. (U.S.), Merck & Co. (U.S.), Sigma-Aldrich Corporation (U.S.), Genedata AG(Switzerland), Cayman chemical company (U.S), Active Motif (U.S.), Thermo Fisher Scientific, Inc., (U.S.), Diagenode, Inc. (Belgium), Zymo Research Corporation (U.S.). and Episona Inc. (U.S).
In October 2016 Episode an epigenetics data company launched SEED a novel male fertility test to evaluate epigenetic changes on DNA to detect a risk of infertility and poor embryo development.
In June 2011, Cayman chemical company has adopted Genedata screener of Genedata, the company of advanced software solutions for drug discovery and life science research as a data management platform for cayman’s new epigenetic screening laboratory.
Market Outline: Global Epigenetics Market
The surge in the prevalence of cancer, improving funds and aids for the R&D activities, rise in the partnerships between pharmaceutical and biotechnology companies and research institutes, increase in epigenetics application in non-oncology diseases will propel the epigenetics. Moreover, improved advancements in epigenetics technology, untapped potential of emerging markets like India and China are expected to offer many opportunities for the growth of epigenetics market. However, high instrument cost and the dearth of skilled personnel are expected to hamper the growth of the epigenetics market.
The Epigenetics Market is classified on the basis of enzymes, kits and assays, instruments, application, end user, and geography.
Based on enzymes, the Epigenetics Market is segmented into the following
DNA polymerase
Acetylases
DNA ligases
Methyltransferase
RNA ligases
Reverse Transcriptase
Others
Based on instruments, the epigenetics Market is segmented into the following
Next generation sequencers
Mass spectrometers
Sonicators
qPCRs
Others
Based on application, the epigenetics market is segmented into the following
Oncology
Cardiovascular diseases
Metabolic diseases
Inflammatory diseases
Infectious diseases
Based on kits and assays, the epigenetics Market is segmented into the following
Deep sequencing kit
Bisulfate conversion kit
Methyltransferase assays
Chip- seq kits
Immunoprecipitation kits
Histone assay
Based on end-user, the epigenetics Market is segmented into the following
Pharmaceutical and biotechnological companies
Contract research companies
Academic and Research Institutes
Epigenetics has triggered R&D for new drugs for various cancers, chronic and autoimmune disorders. For example, U.S.FDA approved ramucirumab/Cyramza by Eli Lilly for use in combination with folfiri to treat metastatic colorectal cancer and Novartis’s Farydak and Celgene’s Istodax received FDA approval in 2015. Introduction of advanced technologies and potential investments on R&D activities are expected to fuel the growth of epigenetics. Currently, companies are focussing on detection of DNA methylation patterns and histone modification. For example, Epigenomic’s EPI ProColon 1.0, Quest Diagnostic’s ColoVantage, Abbott’s Real Time mS9 are few tests which detect SepT9 DNA methylation biomarker for colorectal carcinoma. Development of high specific antibodies for accurate and rapid detection of modifications of histone core proteins. For example, Abcam developed a multiplex assay kit for the detection of various core histone protein modifications.
Geographically Epigenetics Market is segmented as Latin America, Europe, Asia- Pacific, North America, The Middle East & Africa. North America is expected to account for the largest market share in the regional market of epigenetics due to rise in prevalence of cancer, high funding on R&D, increasing acquisitions and collaborations among large pharma companies, high adaptation and awareness of new technologies and healthcare infrastructure. Asia Pacific is a lucrative market owing to the presence of favourable regulatory framework, high incidence and prevalence of diabetes, cancer and cardiovascular diseases among the population of Asia Pacific countries. Mexico, Brazil, and South Africa are expected to show significant growth due to rising economy, a high prevalence of diseases and presence of high unmet needs.
Some of the players in epigenetics market Illumina, Inc. (U.S.), Abcam plc. (U.K), QIAGEN N.V. (Netherland), New England Biolabs, Inc. (U.S.), Merck & Co. (U.S.), Sigma-Aldrich Corporation (U.S.), Genedata AG(Switzerland), Cayman chemical company (U.S), Active Motif (U.S.), Thermo Fisher Scientific, Inc., (U.S.), Diagenode, Inc. (Belgium), Zymo Research Corporation (U.S.). and Episona Inc. (U.S).
In October 2016 Episode an epigenetics data company launched SEED a novel male fertility test to evaluate epigenetic changes on DNA to detect a risk of infertility and poor embryo development.
In June 2011, Cayman chemical company has adopted Genedata screener of Genedata, the company of advanced software solutions for drug discovery and life science research as a data management platform for cayman’s new epigenetic screening laboratory.
1. EXECUTIVE SUMMARY
2. GLOBAL EPIGENETICS MARKET INTRODUCTION
2.1. Global Epigenetics Market – Taxonomy
2.2. Global Epigenetics Market –Definitions
2.2.1. Enzyme
2.2.2. Instruments
2.2.3. Application
2.2.4. Kits
2.2.5. End-User
3. GLOBAL EPIGENETICS MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Epigenetics Market Dynamics – Factors Impact Analysis
3.6. Global Epigenetics Market – Regulations
3.6.1. U.S.
3.6.2. Europe
4. GLOBAL EPIGENETICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL EPIGENETICS MARKET , BY ENZYME, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. DNA polymerase
5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Acetylases
5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. DNA ligases
5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Methyltransferase
5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. RNA ligases
5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Reverse Transcriptase
5.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
5.7. Others
5.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.7.3. Market Opportunity Analysis
6. GLOBAL EPIGENETICS MARKET FORECAST, BY INSTRUMENT, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Next generation sequencers
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Mass spectrometers
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Sonicators
6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. qPCRs
6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Others
6.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
7. GLOBAL EPIGENETICS MARKET FORECAST, BY APPLICATION, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Oncology
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Cardiovascular diseases
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Metabolic diseases
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Inflammatory diseases
7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Infectious diseases
7.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
8. GLOBAL EPIGENETICS MARKET FORECAST, BY KITS & ASSAY, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. Deep sequencing kit
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Bisulfate conversion kit
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Methyltransferase assays
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Chip- seq kits
8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Immunoprecipitation kits
8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Histone assay
8.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.6.3. Market Opportunity Analysis
9. GLOBAL EPIGENETICS MARKET FORECAST, BY END-USER, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1. Pharmaceutical and biotechnological companies
9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.1.3. Market Opportunity Analysis
9.2. Contract research companies
9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.2.3. Market Opportunity Analysis
9.3. Academic and Research Institutes
9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.3.3. Market Opportunity Analysis
10. GLOBAL EPIGENETICS MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1. North America
10.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
10.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.1.3. Market Opportunity Analysis
10.2. Europe
10.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
10.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.2.3. Market Opportunity Analysis
10.3. Asia-Pacific
10.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
10.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.3.3. Market Opportunity Analysis
10.4. Latin America
10.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
10.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.4.3. Market Opportunity Analysis
10.5. Middle East and Africa
10.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
10.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.5.3. Market Opportunity Analysis
10.6. Global Epigenetics Market - Opportunity Analysis Index, By Enzyme, By Instrument, By Application, By Kits & Assays, By End-User, and Region, 2017 – 2023
11. NORTH AMERICA EPIGENETICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1. Enzyme Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. DNA polymerase
11.1.2. Acetylases
11.1.3. DNA ligases
11.1.4. Methyltransferase
11.1.5. RNA ligases
11.1.6. Reverse Transcriptase
11.1.7. Others
11.2. Instrument Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Next generation sequencers
11.2.2. Mass spectrometers
11.2.3. Sonicators
11.2.4. qPCRs
11.2.5. Others
11.3. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Oncology
11.3.2. Cardiovascular diseases
11.3.3. Metabolic diseases
11.3.4. Inflammatory diseases
11.3.5. Infectious diseases
11.4. Kits & Assays Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.4.1. Deep sequencing kit
11.4.2. Bisulfate conversion kit
11.4.3. Methyltransferase assays
11.4.4. Chip- seq kits
11.4.5. Immunoprecipitation kits
11.4.6. Histone assay
11.5. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.5.1. Pharmaceutical and biotechnological companies
11.5.2. Contract research companies
11.5.3. Academic and Research Institutes
11.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.6.1. U.S.
11.6.2. Canada
11.7. North America Epigenetics Market - Opportunity Analysis Index, By Enzyme, By Instrument, By Application, By Kits & Assays, By End-User, and Country, 2017 – 2023
11.8. North America Epigenetics Market Dynamics – Trends
12. EUROPE EPIGENETICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1. Enzyme Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. DNA polymerase
12.1.2. Acetylases
12.1.3. DNA ligases
12.1.4. Methyltransferase
12.1.5. RNA ligases
12.1.6. Reverse Transcriptase
12.1.7. Others
12.2. Instrument Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Next generation sequencers
12.2.2. Mass spectrometers
12.2.3. Sonicators
12.2.4. qPCRs
12.2.5. Others
12.3. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Oncology
12.3.2. Cardiovascular diseases
12.3.3. Metabolic diseases
12.3.4. Inflammatory diseases
12.3.5. Infectious diseases
12.4. Kits & Assays Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.4.1. Deep sequencing kit
12.4.2. Bisulfate conversion kit
12.4.3. Methyltransferase assays
12.4.4. Chip- seq kits
12.4.5. Immunoprecipitation kits
12.4.6. Histone assay
12.5. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.5.1. Pharmaceutical and biotechnological companies
12.5.2. Contract research companies
12.5.3. Academic and Research Institutes
12.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.6.1. Germany
12.6.2. UK
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Russia
12.6.7. Poland
12.6.8. Rest of Europe
12.7. Europe Epigenetics Market - Opportunity Analysis Index, By Enzyme, By Instrument, By Application, By Kits & Assays, By End-User, and Country, 2017 – 2023
12.8. Europe Epigenetics Market Dynamics – Trends
13. ASIA-PACIFIC EPIGENETICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
13.1. Enzyme Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. DNA polymerase
13.1.2. Acetylases
13.1.3. DNA ligases
13.1.4. Methyltransferase
13.1.5. RNA ligases
13.1.6. Reverse Transcriptase
13.1.7. Others
13.2. Instrument Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Next generation sequencers
13.2.2. Mass spectrometers
13.2.3. Sonicators
13.2.4. qPCRs
13.2.5. Others
13.3. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Oncology
13.3.2. Cardiovascular diseases
13.3.3. Metabolic diseases
13.3.4. Inflammatory diseases
13.3.5. Infectious diseases
13.4. Kits & Assays Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.4.1. Deep sequencing kit
13.4.2. Bisulfate conversion kit
13.4.3. Methyltransferase assays
13.4.4. Chip- seq kits
13.4.5. Immunoprecipitation kits
13.4.6. Histone assay
13.5. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.5.1. Pharmaceutical and biotechnological companies
13.5.2. Contract research companies
13.5.3. Academic and Research Institutes
13.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
13.6.1. Japan
13.6.2. China
13.6.3. India
13.6.4. ASEAN
13.6.5. Australia & New Zealand
13.6.6. Rest of Asia-Pacific
13.7. Asia-Pacific Epigenetics Market - Opportunity Analysis Index, By Enzyme, By Instrument, By Application, By Kits & Assays, By End-User, and Country, 2017 – 2023
13.8. Europe Epigenetics Market Dynamics – Trends
14. LATIN AMERICA EPIGENETICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
14.1. Enzyme Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.1. DNA polymerase
14.1.2. Acetylases
14.1.3. DNA ligases
14.1.4. Methyltransferase
14.1.5. RNA ligases
14.1.6. Reverse Transcriptase
14.1.7. Others
14.2. Instrument Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.2.1. Next generation sequencers
14.2.2. Mass spectrometers
14.2.3. Sonicators
14.2.4. qPCRs
14.2.5. Others
14.3. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.3.1. Oncology
14.3.2. Cardiovascular diseases
14.3.3. Metabolic diseases
14.3.4. Inflammatory diseases
14.3.5. Infectious diseases
14.4. Kits & Assays Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.4.1. Deep sequencing kit
14.4.2. Bisulfate conversion kit
14.4.3. Methyltransferase assays
14.4.4. Chip- seq kits
14.4.5. Immunoprecipitation kits
14.4.6. Histone assay
14.5. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.5.1. Pharmaceutical and biotechnological companies
14.5.2. Contract research companies
14.5.3. Academic and Research Institutes
14.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Argentina
14.6.4. Venezuela
14.6.5. Rest of Latin America
14.7. Latin America Epigenetics Market - Opportunity Analysis Index, By Enzyme, By Instrument, By Application, By Kits & Assays, By End-User, and Country, 2017 – 2023
14.8. Latin America Epigenetics Market Dynamics – Trends
15. MIDDLE EAST AND AFRICA EPIGENETICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
15.1. Enzyme Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
15.1.1. DNA polymerase
15.1.2. Acetylases
15.1.3. DNA ligases
15.1.4. Methyltransferase
15.1.5. RNA ligases
15.1.6. Reverse Transcriptase
15.1.7. Others
15.2. Instrument Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
15.2.1. Next generation sequencers
15.2.2. Mass spectrometers
15.2.3. Sonicators
15.2.4. qPCRs
15.2.5. Others
15.3. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
15.3.1. Oncology
15.3.2. Cardiovascular diseases
15.3.3. Metabolic diseases
15.3.4. Inflammatory diseases
15.3.5. Infectious diseases
15.4. Kits & Assays Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
15.4.1. Deep sequencing kit
15.4.2. Bisulfate conversion kit
15.4.3. Methyltransferase assays
15.4.4. Chip- seq kits
15.4.5. Immunoprecipitation kits
15.4.6. Histone assay
15.5. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
15.5.1. Pharmaceutical and biotechnological companies
15.5.2. Contract research companies
15.5.3. Academic and Research Institutes
15.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
15.6.1. Gulf Cooperation Council (GCC) Countries
15.6.2. Israel
15.6.3. South Africa
15.6.4. Rest of MEA
15.7. MEA Epigenetics Market - Opportunity Analysis Index, By Enzyme, By Instrument, By Application, By Kits & Assays, By End-User, and Country, 2017 – 2023
15.8. MEA Epigenetics Market Dynamics – Trends
16. COMPETITION LANDSCAPE
16.1. Strategic Dashboard of Top Market Players
16.2. Company Profiles (Introduction, Financial Analysis, Disease Type & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
16.2.1. Illumina, Inc. (U.S.)
16.2.2. Abcam plc. (U.K)
16.2.3. QIAGEN N.V. (Netherland)
16.2.4. New England Biolabs, Inc. (U.S.)
16.2.5. Merck & Co. (U.S.)
16.2.6. Sigma-Aldrich Corporation (U.S.)
16.2.7. Genedata AG(Switzerland)
16.2.8. Cayman chemical company (U.S)
16.2.9. Active Motif (U.S.)
16.2.10. Thermo Fisher Scientific, Inc., (U.S.)
16.2.11. Diagenode, Inc. (Belgium)
16.2.12. Zymo Research Corporation (U.S.).
16.2.13. Episona Inc. (U.S).
17. RESEARCH METHODOLOGY
18. KEY ASSUMPTIONS AND ACRONYMS
2. GLOBAL EPIGENETICS MARKET INTRODUCTION
2.1. Global Epigenetics Market – Taxonomy
2.2. Global Epigenetics Market –Definitions
2.2.1. Enzyme
2.2.2. Instruments
2.2.3. Application
2.2.4. Kits
2.2.5. End-User
3. GLOBAL EPIGENETICS MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Epigenetics Market Dynamics – Factors Impact Analysis
3.6. Global Epigenetics Market – Regulations
3.6.1. U.S.
3.6.2. Europe
4. GLOBAL EPIGENETICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL EPIGENETICS MARKET , BY ENZYME, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. DNA polymerase
5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Acetylases
5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. DNA ligases
5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Methyltransferase
5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. RNA ligases
5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Reverse Transcriptase
5.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
5.7. Others
5.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.7.3. Market Opportunity Analysis
6. GLOBAL EPIGENETICS MARKET FORECAST, BY INSTRUMENT, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Next generation sequencers
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Mass spectrometers
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Sonicators
6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. qPCRs
6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Others
6.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
7. GLOBAL EPIGENETICS MARKET FORECAST, BY APPLICATION, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Oncology
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Cardiovascular diseases
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Metabolic diseases
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Inflammatory diseases
7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Infectious diseases
7.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
8. GLOBAL EPIGENETICS MARKET FORECAST, BY KITS & ASSAY, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. Deep sequencing kit
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Bisulfate conversion kit
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Methyltransferase assays
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Chip- seq kits
8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Immunoprecipitation kits
8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Histone assay
8.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.6.3. Market Opportunity Analysis
9. GLOBAL EPIGENETICS MARKET FORECAST, BY END-USER, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1. Pharmaceutical and biotechnological companies
9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.1.3. Market Opportunity Analysis
9.2. Contract research companies
9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.2.3. Market Opportunity Analysis
9.3. Academic and Research Institutes
9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.3.3. Market Opportunity Analysis
10. GLOBAL EPIGENETICS MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1. North America
10.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
10.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.1.3. Market Opportunity Analysis
10.2. Europe
10.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
10.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.2.3. Market Opportunity Analysis
10.3. Asia-Pacific
10.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
10.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.3.3. Market Opportunity Analysis
10.4. Latin America
10.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
10.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.4.3. Market Opportunity Analysis
10.5. Middle East and Africa
10.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
10.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.5.3. Market Opportunity Analysis
10.6. Global Epigenetics Market - Opportunity Analysis Index, By Enzyme, By Instrument, By Application, By Kits & Assays, By End-User, and Region, 2017 – 2023
11. NORTH AMERICA EPIGENETICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1. Enzyme Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. DNA polymerase
11.1.2. Acetylases
11.1.3. DNA ligases
11.1.4. Methyltransferase
11.1.5. RNA ligases
11.1.6. Reverse Transcriptase
11.1.7. Others
11.2. Instrument Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Next generation sequencers
11.2.2. Mass spectrometers
11.2.3. Sonicators
11.2.4. qPCRs
11.2.5. Others
11.3. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Oncology
11.3.2. Cardiovascular diseases
11.3.3. Metabolic diseases
11.3.4. Inflammatory diseases
11.3.5. Infectious diseases
11.4. Kits & Assays Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.4.1. Deep sequencing kit
11.4.2. Bisulfate conversion kit
11.4.3. Methyltransferase assays
11.4.4. Chip- seq kits
11.4.5. Immunoprecipitation kits
11.4.6. Histone assay
11.5. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.5.1. Pharmaceutical and biotechnological companies
11.5.2. Contract research companies
11.5.3. Academic and Research Institutes
11.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.6.1. U.S.
11.6.2. Canada
11.7. North America Epigenetics Market - Opportunity Analysis Index, By Enzyme, By Instrument, By Application, By Kits & Assays, By End-User, and Country, 2017 – 2023
11.8. North America Epigenetics Market Dynamics – Trends
12. EUROPE EPIGENETICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1. Enzyme Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. DNA polymerase
12.1.2. Acetylases
12.1.3. DNA ligases
12.1.4. Methyltransferase
12.1.5. RNA ligases
12.1.6. Reverse Transcriptase
12.1.7. Others
12.2. Instrument Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Next generation sequencers
12.2.2. Mass spectrometers
12.2.3. Sonicators
12.2.4. qPCRs
12.2.5. Others
12.3. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Oncology
12.3.2. Cardiovascular diseases
12.3.3. Metabolic diseases
12.3.4. Inflammatory diseases
12.3.5. Infectious diseases
12.4. Kits & Assays Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.4.1. Deep sequencing kit
12.4.2. Bisulfate conversion kit
12.4.3. Methyltransferase assays
12.4.4. Chip- seq kits
12.4.5. Immunoprecipitation kits
12.4.6. Histone assay
12.5. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.5.1. Pharmaceutical and biotechnological companies
12.5.2. Contract research companies
12.5.3. Academic and Research Institutes
12.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.6.1. Germany
12.6.2. UK
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Russia
12.6.7. Poland
12.6.8. Rest of Europe
12.7. Europe Epigenetics Market - Opportunity Analysis Index, By Enzyme, By Instrument, By Application, By Kits & Assays, By End-User, and Country, 2017 – 2023
12.8. Europe Epigenetics Market Dynamics – Trends
13. ASIA-PACIFIC EPIGENETICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
13.1. Enzyme Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. DNA polymerase
13.1.2. Acetylases
13.1.3. DNA ligases
13.1.4. Methyltransferase
13.1.5. RNA ligases
13.1.6. Reverse Transcriptase
13.1.7. Others
13.2. Instrument Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Next generation sequencers
13.2.2. Mass spectrometers
13.2.3. Sonicators
13.2.4. qPCRs
13.2.5. Others
13.3. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Oncology
13.3.2. Cardiovascular diseases
13.3.3. Metabolic diseases
13.3.4. Inflammatory diseases
13.3.5. Infectious diseases
13.4. Kits & Assays Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.4.1. Deep sequencing kit
13.4.2. Bisulfate conversion kit
13.4.3. Methyltransferase assays
13.4.4. Chip- seq kits
13.4.5. Immunoprecipitation kits
13.4.6. Histone assay
13.5. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.5.1. Pharmaceutical and biotechnological companies
13.5.2. Contract research companies
13.5.3. Academic and Research Institutes
13.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
13.6.1. Japan
13.6.2. China
13.6.3. India
13.6.4. ASEAN
13.6.5. Australia & New Zealand
13.6.6. Rest of Asia-Pacific
13.7. Asia-Pacific Epigenetics Market - Opportunity Analysis Index, By Enzyme, By Instrument, By Application, By Kits & Assays, By End-User, and Country, 2017 – 2023
13.8. Europe Epigenetics Market Dynamics – Trends
14. LATIN AMERICA EPIGENETICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
14.1. Enzyme Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.1. DNA polymerase
14.1.2. Acetylases
14.1.3. DNA ligases
14.1.4. Methyltransferase
14.1.5. RNA ligases
14.1.6. Reverse Transcriptase
14.1.7. Others
14.2. Instrument Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.2.1. Next generation sequencers
14.2.2. Mass spectrometers
14.2.3. Sonicators
14.2.4. qPCRs
14.2.5. Others
14.3. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.3.1. Oncology
14.3.2. Cardiovascular diseases
14.3.3. Metabolic diseases
14.3.4. Inflammatory diseases
14.3.5. Infectious diseases
14.4. Kits & Assays Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.4.1. Deep sequencing kit
14.4.2. Bisulfate conversion kit
14.4.3. Methyltransferase assays
14.4.4. Chip- seq kits
14.4.5. Immunoprecipitation kits
14.4.6. Histone assay
14.5. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.5.1. Pharmaceutical and biotechnological companies
14.5.2. Contract research companies
14.5.3. Academic and Research Institutes
14.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Argentina
14.6.4. Venezuela
14.6.5. Rest of Latin America
14.7. Latin America Epigenetics Market - Opportunity Analysis Index, By Enzyme, By Instrument, By Application, By Kits & Assays, By End-User, and Country, 2017 – 2023
14.8. Latin America Epigenetics Market Dynamics – Trends
15. MIDDLE EAST AND AFRICA EPIGENETICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
15.1. Enzyme Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
15.1.1. DNA polymerase
15.1.2. Acetylases
15.1.3. DNA ligases
15.1.4. Methyltransferase
15.1.5. RNA ligases
15.1.6. Reverse Transcriptase
15.1.7. Others
15.2. Instrument Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
15.2.1. Next generation sequencers
15.2.2. Mass spectrometers
15.2.3. Sonicators
15.2.4. qPCRs
15.2.5. Others
15.3. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
15.3.1. Oncology
15.3.2. Cardiovascular diseases
15.3.3. Metabolic diseases
15.3.4. Inflammatory diseases
15.3.5. Infectious diseases
15.4. Kits & Assays Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
15.4.1. Deep sequencing kit
15.4.2. Bisulfate conversion kit
15.4.3. Methyltransferase assays
15.4.4. Chip- seq kits
15.4.5. Immunoprecipitation kits
15.4.6. Histone assay
15.5. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
15.5.1. Pharmaceutical and biotechnological companies
15.5.2. Contract research companies
15.5.3. Academic and Research Institutes
15.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
15.6.1. Gulf Cooperation Council (GCC) Countries
15.6.2. Israel
15.6.3. South Africa
15.6.4. Rest of MEA
15.7. MEA Epigenetics Market - Opportunity Analysis Index, By Enzyme, By Instrument, By Application, By Kits & Assays, By End-User, and Country, 2017 – 2023
15.8. MEA Epigenetics Market Dynamics – Trends
16. COMPETITION LANDSCAPE
16.1. Strategic Dashboard of Top Market Players
16.2. Company Profiles (Introduction, Financial Analysis, Disease Type & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
16.2.1. Illumina, Inc. (U.S.)
16.2.2. Abcam plc. (U.K)
16.2.3. QIAGEN N.V. (Netherland)
16.2.4. New England Biolabs, Inc. (U.S.)
16.2.5. Merck & Co. (U.S.)
16.2.6. Sigma-Aldrich Corporation (U.S.)
16.2.7. Genedata AG(Switzerland)
16.2.8. Cayman chemical company (U.S)
16.2.9. Active Motif (U.S.)
16.2.10. Thermo Fisher Scientific, Inc., (U.S.)
16.2.11. Diagenode, Inc. (Belgium)
16.2.12. Zymo Research Corporation (U.S.).
16.2.13. Episona Inc. (U.S).
17. RESEARCH METHODOLOGY
18. KEY ASSUMPTIONS AND ACRONYMS
